Kolte-Patil Developers Limited
Kolte-Patil Developers Limited (KOLTEPATIL.BO) Stock Competitors & Peer Comparison
See (KOLTEPATIL.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Real Estate - Development Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| KOLTEPATIL.BO | ₹325.90 | +0.31% | 28.7B | 55.24 | ₹5.86 | N/A |
| DLF.NS | ₹521.25 | -3.63% | 1.3T | 28.76 | ₹17.90 | +1.17% |
| DLF.BO | ₹520.85 | -3.29% | 1.3T | 28.75 | ₹17.90 | +1.17% |
| LODHA.BO | ₹730.75 | -8.55% | 727.5B | 21.76 | ₹33.47 | +0.58% |
| LODHA.NS | ₹728.00 | -8.52% | 727B | 21.75 | ₹33.47 | +0.58% |
| OBEROIRLTY.BO | ₹1,427.25 | -1.24% | 513.4B | 22.96 | ₹61.50 | +0.57% |
| OBEROIRLTY.NS | ₹1,430.00 | -1.23% | 513.2B | 22.92 | ₹61.59 | +0.57% |
| GODREJPROP.NS | ₹1,528.90 | -1.43% | 451B | 28.50 | ₹52.53 | N/A |
| GODREJPROP.BO | ₹1,529.40 | -1.29% | 450.9B | 29.03 | ₹51.57 | N/A |
| ANANTRAJ.BO | ₹451.85 | -2.51% | 159.5B | 29.14 | ₹15.21 | +0.17% |
Stock Comparison
KOLTEPATIL.BO vs DLF.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, DLF.NS has a market cap of 1.3T. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while DLF.NS trades at ₹521.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas DLF.NS's P/E ratio is 28.76. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to DLF.NS's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to DLF.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DLF.NS's competition here
KOLTEPATIL.BO vs DLF.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, DLF.BO has a market cap of 1.3T. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while DLF.BO trades at ₹520.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas DLF.BO's P/E ratio is 28.75. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to DLF.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to DLF.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DLF.BO's competition here
KOLTEPATIL.BO vs LODHA.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, LODHA.BO has a market cap of 727.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while LODHA.BO trades at ₹730.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas LODHA.BO's P/E ratio is 21.76. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to LODHA.BO's ROE of +0.16%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to LODHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check LODHA.BO's competition here
KOLTEPATIL.BO vs LODHA.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, LODHA.NS has a market cap of 727B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while LODHA.NS trades at ₹728.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas LODHA.NS's P/E ratio is 21.75. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to LODHA.NS's ROE of +0.16%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to LODHA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check LODHA.NS's competition here
KOLTEPATIL.BO vs OBEROIRLTY.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, OBEROIRLTY.BO has a market cap of 513.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while OBEROIRLTY.BO trades at ₹1,427.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas OBEROIRLTY.BO's P/E ratio is 22.96. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OBEROIRLTY.BO's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OBEROIRLTY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OBEROIRLTY.BO's competition here
KOLTEPATIL.BO vs OBEROIRLTY.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, OBEROIRLTY.NS has a market cap of 513.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while OBEROIRLTY.NS trades at ₹1,430.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas OBEROIRLTY.NS's P/E ratio is 22.92. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OBEROIRLTY.NS's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OBEROIRLTY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OBEROIRLTY.NS's competition here
KOLTEPATIL.BO vs GODREJPROP.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, GODREJPROP.NS has a market cap of 451B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while GODREJPROP.NS trades at ₹1,528.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas GODREJPROP.NS's P/E ratio is 28.50. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GODREJPROP.NS's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GODREJPROP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GODREJPROP.NS's competition here
KOLTEPATIL.BO vs GODREJPROP.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, GODREJPROP.BO has a market cap of 450.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while GODREJPROP.BO trades at ₹1,529.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas GODREJPROP.BO's P/E ratio is 29.03. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GODREJPROP.BO's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GODREJPROP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GODREJPROP.BO's competition here
KOLTEPATIL.BO vs ANANTRAJ.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ANANTRAJ.BO has a market cap of 159.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ANANTRAJ.BO trades at ₹451.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ANANTRAJ.BO's P/E ratio is 29.14. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ANANTRAJ.BO's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ANANTRAJ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ANANTRAJ.BO's competition here
KOLTEPATIL.BO vs ANANTRAJ.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ANANTRAJ.NS has a market cap of 159.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ANANTRAJ.NS trades at ₹447.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ANANTRAJ.NS's P/E ratio is 29.11. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ANANTRAJ.NS's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ANANTRAJ.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ANANTRAJ.NS's competition here
KOLTEPATIL.BO vs BRIGADE.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, BRIGADE.BO has a market cap of 155.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while BRIGADE.BO trades at ₹634.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas BRIGADE.BO's P/E ratio is 20.78. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to BRIGADE.BO's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to BRIGADE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check BRIGADE.BO's competition here
KOLTEPATIL.BO vs BRIGADE.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, BRIGADE.NS has a market cap of 155.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while BRIGADE.NS trades at ₹636.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas BRIGADE.NS's P/E ratio is 20.75. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to BRIGADE.NS's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to BRIGADE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check BRIGADE.NS's competition here
KOLTEPATIL.BO vs SOBHA.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SOBHA.NS has a market cap of 128.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SOBHA.NS trades at ₹1,207.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SOBHA.NS's P/E ratio is 90.14. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SOBHA.NS's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SOBHA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SOBHA.NS's competition here
KOLTEPATIL.BO vs SOBHA.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SOBHA.BO has a market cap of 128.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SOBHA.BO trades at ₹1,208.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SOBHA.BO's P/E ratio is 89.99. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SOBHA.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SOBHA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SOBHA.BO's competition here
KOLTEPATIL.BO vs SIGNATURE.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SIGNATURE.BO has a market cap of 102.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SIGNATURE.BO trades at ₹731.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SIGNATURE.BO's P/E ratio is 3163.26. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SIGNATURE.BO's ROE of +0.00%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SIGNATURE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SIGNATURE.BO's competition here
KOLTEPATIL.BO vs SIGNATURE.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SIGNATURE.NS has a market cap of 102.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SIGNATURE.NS trades at ₹730.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SIGNATURE.NS's P/E ratio is 3158.48. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SIGNATURE.NS's ROE of +0.00%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SIGNATURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SIGNATURE.NS's competition here
KOLTEPATIL.BO vs IBREALEST.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, IBREALEST.BO has a market cap of 95.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while IBREALEST.BO trades at ₹150.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas IBREALEST.BO's P/E ratio is -7.83. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to IBREALEST.BO's ROE of -0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to IBREALEST.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBREALEST.BO's competition here
KOLTEPATIL.BO vs IBREALEST.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, IBREALEST.NS has a market cap of 83.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while IBREALEST.NS trades at ₹131.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas IBREALEST.NS's P/E ratio is -6.85. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to IBREALEST.NS's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to IBREALEST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBREALEST.NS's competition here
KOLTEPATIL.BO vs MAHLIFE.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MAHLIFE.NS has a market cap of 69.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MAHLIFE.NS trades at ₹328.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MAHLIFE.NS's P/E ratio is 21.05. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MAHLIFE.NS's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MAHLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAHLIFE.NS's competition here
KOLTEPATIL.BO vs MAHLIFE.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MAHLIFE.BO has a market cap of 68.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MAHLIFE.BO trades at ₹330.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MAHLIFE.BO's P/E ratio is 20.99. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MAHLIFE.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MAHLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAHLIFE.BO's competition here
KOLTEPATIL.BO vs KALPATARU.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, KALPATARU.NS has a market cap of 58.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while KALPATARU.NS trades at ₹293.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas KALPATARU.NS's P/E ratio is -56.13. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KALPATARU.NS's ROE of -0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KALPATARU.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KALPATARU.NS's competition here
KOLTEPATIL.BO vs MAXESTATES.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MAXESTATES.BO has a market cap of 55.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MAXESTATES.BO trades at ₹352.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MAXESTATES.BO's P/E ratio is 112.83. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MAXESTATES.BO's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MAXESTATES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAXESTATES.BO's competition here
KOLTEPATIL.BO vs MAXESTATES.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MAXESTATES.NS has a market cap of 55.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MAXESTATES.NS trades at ₹351.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MAXESTATES.NS's P/E ratio is 112.67. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MAXESTATES.NS's ROE of +0.01%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MAXESTATES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MAXESTATES.NS's competition here
KOLTEPATIL.BO vs DBREALTY.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, DBREALTY.NS has a market cap of 49.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while DBREALTY.NS trades at ₹92.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas DBREALTY.NS's P/E ratio is 46.92. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to DBREALTY.NS's ROE of +0.02%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to DBREALTY.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DBREALTY.NS's competition here
KOLTEPATIL.BO vs DBREALTY.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, DBREALTY.BO has a market cap of 49B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while DBREALTY.BO trades at ₹92.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas DBREALTY.BO's P/E ratio is 46.86. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to DBREALTY.BO's ROE of +0.02%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to DBREALTY.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check DBREALTY.BO's competition here
KOLTEPATIL.BO vs RUSTOMJEE.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, RUSTOMJEE.NS has a market cap of 46.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while RUSTOMJEE.NS trades at ₹366.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas RUSTOMJEE.NS's P/E ratio is 51.48. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RUSTOMJEE.NS's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RUSTOMJEE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RUSTOMJEE.NS's competition here
KOLTEPATIL.BO vs RUSTOMJEE.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, RUSTOMJEE.BO has a market cap of 46.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while RUSTOMJEE.BO trades at ₹368.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas RUSTOMJEE.BO's P/E ratio is 51.19. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RUSTOMJEE.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RUSTOMJEE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RUSTOMJEE.BO's competition here
KOLTEPATIL.BO vs GANESHHOU.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, GANESHHOU.NS has a market cap of 46.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while GANESHHOU.NS trades at ₹576.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas GANESHHOU.NS's P/E ratio is 11.06. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GANESHHOU.NS's ROE of +0.26%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOU.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOU.NS's competition here
KOLTEPATIL.BO vs GANESHHOU.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, GANESHHOU.BO has a market cap of 46.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while GANESHHOU.BO trades at ₹578.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas GANESHHOU.BO's P/E ratio is 11.05. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GANESHHOU.BO's ROE of +0.26%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOU.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOU.BO's competition here
KOLTEPATIL.BO vs GANESHHOUC.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, GANESHHOUC.NS has a market cap of 46.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while GANESHHOUC.NS trades at ₹576.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas GANESHHOUC.NS's P/E ratio is 8.02. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GANESHHOUC.NS's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOUC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOUC.NS's competition here
KOLTEPATIL.BO vs GANESHHOUC.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, GANESHHOUC.BO has a market cap of 46.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while GANESHHOUC.BO trades at ₹578.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas GANESHHOUC.BO's P/E ratio is 8.00. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GANESHHOUC.BO's ROE of +0.26%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GANESHHOUC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GANESHHOUC.BO's competition here
KOLTEPATIL.BO vs NIRLON.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, NIRLON.BO has a market cap of 43.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while NIRLON.BO trades at ₹488.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas NIRLON.BO's P/E ratio is 13.29. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NIRLON.BO's ROE of +0.84%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NIRLON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NIRLON.BO's competition here
KOLTEPATIL.BO vs SUNTECK.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SUNTECK.BO has a market cap of 42.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SUNTECK.BO trades at ₹299.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SUNTECK.BO's P/E ratio is 22.12. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SUNTECK.BO's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SUNTECK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SUNTECK.BO's competition here
KOLTEPATIL.BO vs SUNTECK.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SUNTECK.NS has a market cap of 42.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SUNTECK.NS trades at ₹297.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SUNTECK.NS's P/E ratio is 22.05. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SUNTECK.NS's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SUNTECK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SUNTECK.NS's competition here
KOLTEPATIL.BO vs PURVA.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, PURVA.NS has a market cap of 39.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while PURVA.NS trades at ₹176.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas PURVA.NS's P/E ratio is -29.28. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PURVA.NS's ROE of -0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PURVA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PURVA.NS's competition here
KOLTEPATIL.BO vs PURVA.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, PURVA.BO has a market cap of 39.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while PURVA.BO trades at ₹180.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas PURVA.BO's P/E ratio is -29.24. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PURVA.BO's ROE of -0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PURVA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PURVA.BO's competition here
KOLTEPATIL.BO vs AGIIL.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, AGIIL.NS has a market cap of 35.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while AGIIL.NS trades at ₹299.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas AGIIL.NS's P/E ratio is 42.78. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to AGIIL.NS's ROE of +0.28%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to AGIIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AGIIL.NS's competition here
KOLTEPATIL.BO vs TARC.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, TARC.NS has a market cap of 33.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while TARC.NS trades at ₹117.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas TARC.NS's P/E ratio is -38.91. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to TARC.NS's ROE of -0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to TARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check TARC.NS's competition here
KOLTEPATIL.BO vs TARC.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, TARC.BO has a market cap of 33.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while TARC.BO trades at ₹117.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas TARC.BO's P/E ratio is -38.63. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to TARC.BO's ROE of -0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to TARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check TARC.BO's competition here
KOLTEPATIL.BO vs KESAR.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, KESAR.BO has a market cap of 32.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while KESAR.BO trades at ₹1,168.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas KESAR.BO's P/E ratio is 174.46. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KESAR.BO's ROE of +0.40%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to KESAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KESAR.BO's competition here
KOLTEPATIL.BO vs ASHIANA.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ASHIANA.BO has a market cap of 29.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ASHIANA.BO trades at ₹294.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ASHIANA.BO's P/E ratio is 24.79. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ASHIANA.BO's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ASHIANA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASHIANA.BO's competition here
KOLTEPATIL.BO vs ASHIANA.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ASHIANA.NS has a market cap of 29.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ASHIANA.NS trades at ₹292.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ASHIANA.NS's P/E ratio is 24.80. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ASHIANA.NS's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ASHIANA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASHIANA.NS's competition here
KOLTEPATIL.BO vs KOLTEPATIL.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, KOLTEPATIL.NS has a market cap of 28.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while KOLTEPATIL.NS trades at ₹324.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas KOLTEPATIL.NS's P/E ratio is 54.95. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KOLTEPATIL.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KOLTEPATIL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KOLTEPATIL.NS's competition here
KOLTEPATIL.BO vs MARATHON.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MARATHON.BO has a market cap of 27.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MARATHON.BO trades at ₹411.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MARATHON.BO's P/E ratio is 11.18. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MARATHON.BO's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MARATHON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MARATHON.BO's competition here
KOLTEPATIL.BO vs MARATHON.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MARATHON.NS has a market cap of 27.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MARATHON.NS trades at ₹407.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MARATHON.NS's P/E ratio is 11.15. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MARATHON.NS's ROE of +0.15%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MARATHON.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MARATHON.NS's competition here
KOLTEPATIL.BO vs NATIONSTD.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, NATIONSTD.BO has a market cap of 27B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while NATIONSTD.BO trades at ₹1,350.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas NATIONSTD.BO's P/E ratio is 222.77. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NATIONSTD.BO's ROE of +0.04%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to NATIONSTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NATIONSTD.BO's competition here
KOLTEPATIL.BO vs HUBTOWN.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, HUBTOWN.BO has a market cap of 26.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while HUBTOWN.BO trades at ₹190.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas HUBTOWN.BO's P/E ratio is 20.64. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to HUBTOWN.BO's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to HUBTOWN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HUBTOWN.BO's competition here
KOLTEPATIL.BO vs HUBTOWN.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, HUBTOWN.NS has a market cap of 26.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while HUBTOWN.NS trades at ₹189.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas HUBTOWN.NS's P/E ratio is 20.63. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to HUBTOWN.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to HUBTOWN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HUBTOWN.NS's competition here
KOLTEPATIL.BO vs ARVSMART.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ARVSMART.NS has a market cap of 23.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ARVSMART.NS trades at ₹513.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ARVSMART.NS's P/E ratio is 32.23. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARVSMART.NS's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARVSMART.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARVSMART.NS's competition here
KOLTEPATIL.BO vs ARVSMART.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ARVSMART.BO has a market cap of 23.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ARVSMART.BO trades at ₹521.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ARVSMART.BO's P/E ratio is 31.90. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARVSMART.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARVSMART.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARVSMART.BO's competition here
KOLTEPATIL.BO vs IBULLSLTD.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, IBULLSLTD.BO has a market cap of 21.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while IBULLSLTD.BO trades at ₹9.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas IBULLSLTD.BO's P/E ratio is -1.55. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to IBULLSLTD.BO's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to IBULLSLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBULLSLTD.BO's competition here
KOLTEPATIL.BO vs IBULLSLTD.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, IBULLSLTD.NS has a market cap of 21.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while IBULLSLTD.NS trades at ₹9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas IBULLSLTD.NS's P/E ratio is -1.55. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to IBULLSLTD.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to IBULLSLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check IBULLSLTD.NS's competition here
KOLTEPATIL.BO vs AJMERA.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, AJMERA.BO has a market cap of 19.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while AJMERA.BO trades at ₹103.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas AJMERA.BO's P/E ratio is 15.23. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to AJMERA.BO's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to AJMERA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AJMERA.BO's competition here
KOLTEPATIL.BO vs AJMERA.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, AJMERA.NS has a market cap of 19.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while AJMERA.NS trades at ₹100.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas AJMERA.NS's P/E ratio is 15.17. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to AJMERA.NS's ROE of +0.10%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to AJMERA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AJMERA.NS's competition here
KOLTEPATIL.BO vs ALEMBICLTD.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ALEMBICLTD.BO has a market cap of 19.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ALEMBICLTD.BO trades at ₹76.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ALEMBICLTD.BO's P/E ratio is 5.96. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ALEMBICLTD.BO's ROE of +0.13%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ALEMBICLTD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ALEMBICLTD.BO's competition here
KOLTEPATIL.BO vs ARKADE.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ARKADE.NS has a market cap of 18.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ARKADE.NS trades at ₹100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ARKADE.NS's P/E ratio is 12.70. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARKADE.NS's ROE of +0.17%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARKADE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARKADE.NS's competition here
KOLTEPATIL.BO vs ASL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ASL.BO has a market cap of 12.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ASL.BO trades at ₹310.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ASL.BO's P/E ratio is -1320.85. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ASL.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ASL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ASL.BO's competition here
KOLTEPATIL.BO vs OMAXE.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, OMAXE.BO has a market cap of 12.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while OMAXE.BO trades at ₹70.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas OMAXE.BO's P/E ratio is -1.92. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OMAXE.BO's ROE of +3.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OMAXE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OMAXE.BO's competition here
KOLTEPATIL.BO vs OMAXE.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, OMAXE.NS has a market cap of 12.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while OMAXE.NS trades at ₹69.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas OMAXE.NS's P/E ratio is -1.91. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OMAXE.NS's ROE of +3.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OMAXE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OMAXE.NS's competition here
KOLTEPATIL.BO vs MIIL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MIIL.BO has a market cap of 11.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MIIL.BO trades at ₹561.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MIIL.BO's P/E ratio is 1571.43. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MIIL.BO's ROE of +0.45%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MIIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MIIL.BO's competition here
KOLTEPATIL.BO vs SHRIRAMPPS.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SHRIRAMPPS.NS has a market cap of 11.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SHRIRAMPPS.NS trades at ₹66.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SHRIRAMPPS.NS's P/E ratio is 16.08. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SHRIRAMPPS.NS's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SHRIRAMPPS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SHRIRAMPPS.NS's competition here
KOLTEPATIL.BO vs SHRIRAMPPS.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SHRIRAMPPS.BO has a market cap of 11.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SHRIRAMPPS.BO trades at ₹66.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SHRIRAMPPS.BO's P/E ratio is 16.08. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SHRIRAMPPS.BO's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SHRIRAMPPS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SHRIRAMPPS.BO's competition here
KOLTEPATIL.BO vs ARIHANT.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ARIHANT.BO has a market cap of 9.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ARIHANT.BO trades at ₹989.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ARIHANT.BO's P/E ratio is 15.30. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARIHANT.BO's ROE of +0.25%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to ARIHANT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANT.BO's competition here
KOLTEPATIL.BO vs RDBRIL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, RDBRIL.BO has a market cap of 9.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while RDBRIL.BO trades at ₹53.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas RDBRIL.BO's P/E ratio is 213.12. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RDBRIL.BO's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RDBRIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RDBRIL.BO's competition here
KOLTEPATIL.BO vs SURAJEST.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SURAJEST.NS has a market cap of 9.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SURAJEST.NS trades at ₹197.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SURAJEST.NS's P/E ratio is 10.00. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SURAJEST.NS's ROE of +0.12%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SURAJEST.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SURAJEST.NS's competition here
KOLTEPATIL.BO vs ARIHANTSUP.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ARIHANTSUP.BO has a market cap of 8.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ARIHANTSUP.BO trades at ₹205.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ARIHANTSUP.BO's P/E ratio is 20.54. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARIHANTSUP.BO's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANTSUP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANTSUP.BO's competition here
KOLTEPATIL.BO vs ARIHANTSUP.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, ARIHANTSUP.NS has a market cap of 8.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while ARIHANTSUP.NS trades at ₹201.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas ARIHANTSUP.NS's P/E ratio is 20.50. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to ARIHANTSUP.NS's ROE of +0.08%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to ARIHANTSUP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check ARIHANTSUP.NS's competition here
KOLTEPATIL.BO vs MCCHRLS-B.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MCCHRLS-B.BO has a market cap of 8.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MCCHRLS-B.BO trades at ₹647.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MCCHRLS-B.BO's P/E ratio is -5.89. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MCCHRLS-B.BO's ROE of -1.38%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to MCCHRLS-B.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MCCHRLS-B.BO's competition here
KOLTEPATIL.BO vs AGIIL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, AGIIL.BO has a market cap of 7.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while AGIIL.BO trades at ₹300.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas AGIIL.BO's P/E ratio is 42.50. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to AGIIL.BO's ROE of +0.28%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to AGIIL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check AGIIL.BO's competition here
KOLTEPATIL.BO vs HAZOOR.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, HAZOOR.BO has a market cap of 6.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while HAZOOR.BO trades at ₹25.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas HAZOOR.BO's P/E ratio is 28.04. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to HAZOOR.BO's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to HAZOOR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check HAZOOR.BO's competition here
KOLTEPATIL.BO vs MODIS.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MODIS.BO has a market cap of 5.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MODIS.BO trades at ₹304.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MODIS.BO's P/E ratio is 23.26. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MODIS.BO's ROE of +0.37%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MODIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MODIS.BO's competition here
KOLTEPATIL.BO vs OSWALAGRO.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, OSWALAGRO.BO has a market cap of 5.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while OSWALAGRO.BO trades at ₹41.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas OSWALAGRO.BO's P/E ratio is 6.19. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OSWALAGRO.BO's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OSWALAGRO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OSWALAGRO.BO's competition here
KOLTEPATIL.BO vs OSWALAGRO.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, OSWALAGRO.NS has a market cap of 5.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while OSWALAGRO.NS trades at ₹40.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas OSWALAGRO.NS's P/E ratio is 6.14. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to OSWALAGRO.NS's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to OSWALAGRO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check OSWALAGRO.NS's competition here
KOLTEPATIL.BO vs GEECEE.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, GEECEE.BO has a market cap of 5.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while GEECEE.BO trades at ₹245.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas GEECEE.BO's P/E ratio is 22.86. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GEECEE.BO's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GEECEE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GEECEE.BO's competition here
KOLTEPATIL.BO vs GEECEE.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, GEECEE.NS has a market cap of 5.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while GEECEE.NS trades at ₹249.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas GEECEE.NS's P/E ratio is 22.83. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to GEECEE.NS's ROE of +0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to GEECEE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check GEECEE.NS's competition here
KOLTEPATIL.BO vs PENINLAND.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, PENINLAND.NS has a market cap of 4.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while PENINLAND.NS trades at ₹14.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas PENINLAND.NS's P/E ratio is -7.60. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PENINLAND.NS's ROE of -0.28%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PENINLAND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PENINLAND.NS's competition here
KOLTEPATIL.BO vs PENINLAND.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, PENINLAND.BO has a market cap of 4.9B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while PENINLAND.BO trades at ₹15.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas PENINLAND.BO's P/E ratio is -7.58. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PENINLAND.BO's ROE of -0.28%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PENINLAND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PENINLAND.BO's competition here
KOLTEPATIL.BO vs NILASPACES.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, NILASPACES.BO has a market cap of 4.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while NILASPACES.BO trades at ₹12.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas NILASPACES.BO's P/E ratio is 19.54. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NILASPACES.BO's ROE of +0.17%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NILASPACES.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILASPACES.BO's competition here
KOLTEPATIL.BO vs NILASPACES.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, NILASPACES.NS has a market cap of 4.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while NILASPACES.NS trades at ₹12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas NILASPACES.NS's P/E ratio is 19.48. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NILASPACES.NS's ROE of +0.17%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NILASPACES.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILASPACES.NS's competition here
KOLTEPATIL.BO vs PANSARI.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, PANSARI.NS has a market cap of 4.6B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while PANSARI.NS trades at ₹271.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas PANSARI.NS's P/E ratio is 27.33. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PANSARI.NS's ROE of +0.11%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to PANSARI.NS. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PANSARI.NS's competition here
KOLTEPATIL.BO vs YOGI.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, YOGI.BO has a market cap of 4.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while YOGI.BO trades at ₹163.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas YOGI.BO's P/E ratio is 34.25. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to YOGI.BO's ROE of +0.18%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to YOGI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check YOGI.BO's competition here
KOLTEPATIL.BO vs SBGLP.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SBGLP.BO has a market cap of 4.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SBGLP.BO trades at ₹25.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SBGLP.BO's P/E ratio is 13.82. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SBGLP.BO's ROE of +0.44%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SBGLP.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SBGLP.BO's competition here
KOLTEPATIL.BO vs SBGLP.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SBGLP.NS has a market cap of 4.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SBGLP.NS trades at ₹24.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SBGLP.NS's P/E ratio is 13.62. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SBGLP.NS's ROE of +0.44%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SBGLP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SBGLP.NS's competition here
KOLTEPATIL.BO vs RATNABHUMI.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, RATNABHUMI.BO has a market cap of 3.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while RATNABHUMI.BO trades at ₹235.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas RATNABHUMI.BO's P/E ratio is 61.41. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RATNABHUMI.BO's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RATNABHUMI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RATNABHUMI.BO's competition here
KOLTEPATIL.BO vs PARSVNATH.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, PARSVNATH.NS has a market cap of 2.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while PARSVNATH.NS trades at ₹6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas PARSVNATH.NS's P/E ratio is -0.64. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PARSVNATH.NS's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PARSVNATH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PARSVNATH.NS's competition here
KOLTEPATIL.BO vs PARSVNATH.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, PARSVNATH.BO has a market cap of 2.8B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while PARSVNATH.BO trades at ₹6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas PARSVNATH.BO's P/E ratio is -0.85. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to PARSVNATH.BO's ROE of +0.22%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to PARSVNATH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check PARSVNATH.BO's competition here
KOLTEPATIL.BO vs NILAINFRA.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, NILAINFRA.NS has a market cap of 2.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while NILAINFRA.NS trades at ₹6.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas NILAINFRA.NS's P/E ratio is 11.72. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NILAINFRA.NS's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NILAINFRA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILAINFRA.NS's competition here
KOLTEPATIL.BO vs NILAINFRA.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, NILAINFRA.BO has a market cap of 2.7B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while NILAINFRA.BO trades at ₹6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas NILAINFRA.BO's P/E ratio is 11.66. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to NILAINFRA.BO's ROE of +0.14%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to NILAINFRA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check NILAINFRA.BO's competition here
KOLTEPATIL.BO vs KBCGLOBAL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, KBCGLOBAL.BO has a market cap of 2.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while KBCGLOBAL.BO trades at ₹0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas KBCGLOBAL.BO's P/E ratio is -8.00. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KBCGLOBAL.BO's ROE of -0.04%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KBCGLOBAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KBCGLOBAL.BO's competition here
KOLTEPATIL.BO vs KBCGLOBAL.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, KBCGLOBAL.NS has a market cap of 2.5B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while KBCGLOBAL.NS trades at ₹0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas KBCGLOBAL.NS's P/E ratio is -9.40. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to KBCGLOBAL.NS's ROE of -0.03%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to KBCGLOBAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check KBCGLOBAL.NS's competition here
KOLTEPATIL.BO vs EMAMIREAL.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, EMAMIREAL.NS has a market cap of 2.4B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while EMAMIREAL.NS trades at ₹55.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas EMAMIREAL.NS's P/E ratio is -1.09. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to EMAMIREAL.NS's ROE of +1.53%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to EMAMIREAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check EMAMIREAL.NS's competition here
KOLTEPATIL.BO vs EMAMIREAL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, EMAMIREAL.BO has a market cap of 2.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while EMAMIREAL.BO trades at ₹55.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas EMAMIREAL.BO's P/E ratio is -1.08. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to EMAMIREAL.BO's ROE of +1.53%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to EMAMIREAL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check EMAMIREAL.BO's competition here
KOLTEPATIL.BO vs SVGLOBAL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SVGLOBAL.BO has a market cap of 2.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SVGLOBAL.BO trades at ₹128.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SVGLOBAL.BO's P/E ratio is 39.97. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SVGLOBAL.BO's ROE of +0.09%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to SVGLOBAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SVGLOBAL.BO's competition here
KOLTEPATIL.BO vs YAARI.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, YAARI.NS has a market cap of 2.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while YAARI.NS trades at ₹21.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas YAARI.NS's P/E ratio is -3.23. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to YAARI.NS's ROE of -0.12%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to YAARI.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check YAARI.NS's competition here
KOLTEPATIL.BO vs YAARI.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, YAARI.BO has a market cap of 2.3B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while YAARI.BO trades at ₹20.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas YAARI.BO's P/E ratio is -3.29. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to YAARI.BO's ROE of +0.05%. Regarding short-term risk, KOLTEPATIL.BO is more volatile compared to YAARI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check YAARI.BO's competition here
KOLTEPATIL.BO vs VIPUL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, VIPUL.BO has a market cap of 2.2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while VIPUL.BO trades at ₹18.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas VIPUL.BO's P/E ratio is -5.46. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to VIPUL.BO's ROE of -0.10%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to VIPUL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check VIPUL.BO's competition here
KOLTEPATIL.BO vs MERCANTILE.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, MERCANTILE.BO has a market cap of 2.1B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while MERCANTILE.BO trades at ₹19.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas MERCANTILE.BO's P/E ratio is 16.86. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to MERCANTILE.BO's ROE of +0.04%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to MERCANTILE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check MERCANTILE.BO's competition here
KOLTEPATIL.BO vs RVHL.BO Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, RVHL.BO has a market cap of 2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while RVHL.BO trades at ₹33.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas RVHL.BO's P/E ratio is 4.02. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to RVHL.BO's ROE of +0.20%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to RVHL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check RVHL.BO's competition here
KOLTEPATIL.BO vs SUMIT.NS Comparison March 2026
KOLTEPATIL.BO plays a significant role within the Real Estate sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, KOLTEPATIL.BO stands at 28.7B. In comparison, SUMIT.NS has a market cap of 2B. Regarding current trading prices, KOLTEPATIL.BO is priced at ₹325.90, while SUMIT.NS trades at ₹46.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
KOLTEPATIL.BO currently has a P/E ratio of 55.24, whereas SUMIT.NS's P/E ratio is 21.04. In terms of profitability, KOLTEPATIL.BO's ROE is +0.05%, compared to SUMIT.NS's ROE of +0.06%. Regarding short-term risk, KOLTEPATIL.BO is less volatile compared to SUMIT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for KOLTEPATIL.BO.Check SUMIT.NS's competition here